JPMorgan analyst Anupam Rama raised his price target for Sarepta Therapeutics to $95 citing the positive regulatory update for golodirsen in the U.S. earlier in the week. The drugmaker closed yesterday up $1.80 to $80.90. Sarepta seeking accelerated approval of golodirsen following guidance from the FDA has a positive read-through for casimersen, Rama tells investors in a research note. He sees the U.S. regulatory process for golodirsen and read-through to casimersen as a "best case scenario." The analyst increased the probability of success for both products in the U.S. and keeps an Overweight rating on Sarepta.